Structured surveillance of Achromobacter, Pandoraea and Ralstonia species from patients in England with cystic fibrosis

 and members of the UK CF Surveillance Working Group., The UK CF Surveillance Working Group comprised

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

A structured survey of the cystic fibrosis pathogens Achromobacter, Pandoraea and Ralstonia species from thirteen sentinel hospitals throughout England was undertaken by Public Health England. One isolate per patient of these genera collected from CF patients during the seven-month survey period in 2015 was requested from participating hospitals. Species-level identification was performed using nrdA/gyrB sequence cluster analysis, and genotyping by pulsed-field gel electrophoresis. In total, 176 isolates were included in the survey; 138 Achromobacter spp. (78.4%), 29 Pandoraea spp. (16.5%) and 9 Ralstonia spp. (5.1%). Novel Achromobacter and Pandoraea clusters were identified. High levels of antimicrobial resistance were found, particularly among Pandoraea isolates. Genotyping analysis revealed considerable diversity, however one geographically-widespread cluster of A. xylosoxidans isolates from six hospitals was found, in addition to two other clusters, both comprising isolates from two hospitals, either derived from the same region (A. xylosoxidans), or from hospitals within the same city (P. apista).

Original languageEnglish
Pages (from-to)388-393
Number of pages6
JournalJournal of Cystic Fibrosis
Volume19
Issue number3
DOIs
Publication statusPublished - May 2020

Bibliographical note

Funding Information:
This study used PHE reference laboratory funding and did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have no personal conflicts of interest to declare. However, PHE's AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Accelerate Diagnostics, Achaogen Inc, Allecra Therapeutics, Amplex, AstraZeneca UK Ltd, Basilea Pharmaceutica, Becton Dickinson Diagnostics, BioM?rieux, Bio-Rad Laboratories, The British Society for Antimicrobial Chemotherapy (BSAC), Cepheid, Check-Points B.V, Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics Ltd. Food Standards Agency, Glaxo Smithkline Services Ltd, Henry Stewart Talks, IHMA Ltd, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp, Meiji Seika Pharma Co. Ltd, Mobidiag, Momentum Biosciences Ltd. Nordic Pharma Ltd. Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith & Nephew UK Ltd, Trius Therapeutics, VenatoRx and Wockhardt Ltd. We would like to thank staff at Public Health England's Genomic Services and Development Unit for sequencing services and Daniel Lilley for help with identification by nrdA/gyrB sequence cluster analysis. We are also grateful to Katie Hopkins and Rachel Pike of PHE's Antimicrobial Resistance and Mechanisms service for guidance, and the use of ceftazidime-avibactam and ceftolozane-tazobactam data.

Funding Information:
The authors have no personal conflicts of interest to declare. However, PHE's AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Accelerate Diagnostics, Achaogen Inc, Allecra Therapeutics, Amplex, AstraZeneca UK Ltd, Basilea Pharmaceutica, Becton Dickinson Diagnostics, BioMérieux, Bio-Rad Laboratories, The British Society for Antimicrobial Chemotherapy (BSAC), Cepheid, Check-Points B.V, Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics Ltd., Food Standards Agency, Glaxo Smithkline Services Ltd, Henry Stewart Talks, IHMA Ltd, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp, Meiji Seika Pharma Co., Ltd, Mobidiag, Momentum Biosciences Ltd., Nordic Pharma Ltd., Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith & Nephew UK Ltd, Trius Therapeutics, VenatoRx and Wockhardt Ltd.

Funding Information:
This study used PHE reference laboratory funding and did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher Copyright:
© 2019

Keywords

  • Achromobacter
  • CF
  • Pandoraea
  • Ralstonia
  • Survey

Fingerprint

Dive into the research topics of 'Structured surveillance of Achromobacter, Pandoraea and Ralstonia species from patients in England with cystic fibrosis'. Together they form a unique fingerprint.

Cite this